HER2-NEGATIVE BREAST CANCER

This study is testing whether adding an experimental drug called Onvansertib to standard chemotherapy (Paclitaxel) is safe and effective for people with advanced triple-negative breast cancer that has spread. About 50 participants with this aggressive cancer type will receive the…

This study is testing whether adding an immunotherapy drug (pembrolizumab) to a targeted cancer drug (sacituzumab govitecan) works better to control advanced breast cancer than the targeted drug alone. It involves about 110 adults with a specific type of breast cancer (HR+/HER2-)…

This study is for people with HER2-negative breast cancer who still have cancer cells after initial (neoadjuvant) chemotherapy, putting them at high risk of the cancer coming back. It compares a newer, targeted drug called sacituzumab govitecan against standard follow-up treatmen…

This study is testing a new drug called NUV-1511 in adults with advanced solid tumors that have stopped responding to standard treatments. The first part checks the drug's safety and finds the right dose, while the second part looks at how well it shrinks tumors in specific cance…

This study is testing whether giving hormone therapy pills for 6 months before breast cancer surgery helps surgeons remove all the cancer in one operation. It involves postmenopausal women with early-stage, hormone-sensitive breast cancer who haven't spread to lymph nodes. The go…

This study is testing a new drug called azenosertib, combined with two existing cancer drugs, for people with advanced triple-negative breast cancer that has spread. The main goals are to find a safe dose and see if the combination makes tumors shrink. About 78 participants will …

This early-stage trial is testing an experimental radioactive drug called RYZ101 for people with advanced ER+ breast cancer that has spread and stopped responding to standard treatments. The study aims to find a safe dose and see if the drug can shrink tumors in patients whose ca…

This study is testing whether adding the drug alpelisib to standard hormone therapy can help control advanced breast cancer that has a specific genetic change (PIK3CA mutation) and has stopped responding to hormone therapy alone. It will involve about 44 adults with this type of …

This early-stage trial is testing the safety and finding the right dose of a two-drug combination (naptumomab estafenatox and durvalumab) for people with advanced or metastatic solid tumors. It will enroll about 120 adults with one of many eligible cancer types, including breast,…

This large study compares different hormone therapy approaches given before surgery to shrink breast cancer tumors in postmenopausal women. Researchers are testing whether newer drug combinations work better than the current standard treatment at controlling cancer growth and pre…

This study is testing whether switching breast cancer treatment earlier, based on a blood test that detects cancer DNA, helps control the disease longer than waiting for standard scans to show it's getting worse. It involves 24 people with advanced, hormone-positive breast cancer…